Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

Plaintiffs say the company misrepresented the promise of nimacimab after a trial update reported the primary goal was not met.

Overview

Rosen Law Firm and other plaintiffs' firms are urging investors to act before the January 16, 2026 cutoff to seek lead-plaintiff status in the securities case against Skye Bioscience.
The lawsuits target purchasers of Skye securities from November 4, 2024 through October 3, 2025, the period defined in the complaints.
Filed complaints allege Skye overstated nimacimab’s effectiveness and exaggerated its clinical, regulatory, and commercial prospects, rendering public statements misleading.
On October 6, 2025, Skye reported topline Phase 2a CBeyond data showing the primary weight-loss endpoint was not met, and the stock closed down 60% at $1.90 that day.
No class has been certified, and investors may share in any potential recovery without serving as lead plaintiff, according to firm notices.